repifermin

Repifermin is a recombinant human keratinocyte growth factor 2 (KGF-2), also known as fibroblast growth factor 10 (FGF-10). It is a member of the fibroblast growth factor family and acts as an agonist at the Fibroblast growth factor receptor 1 (FGFR1) and Fibroblast growth factor receptor 2 (FGFR2). Repifermin was developed to promote epithelial cell proliferation, enhance wound healing, and reduce inflammation in various conditions such as chronic venous ulcers, mucositis, neutropenia, and ulcerative colitis. Preclinical studies demonstrated its ability to accelerate wound healing and improve mucosal transport in animal models of colitis. Clinical trials showed that it was well tolerated but did not demonstrate significant efficacy for ulcerative colitis or other indications at tested doses. Development has been discontinued for all investigated indications[1][4][7].

Brand names

repifermin

Other names

repiferminkeratinocyte growth factor 2fibroblast growth factor 10